Profound Medical
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell PROF and other ETFs, options, and stocks.About PROF
Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The firm’s product, the TULSA-PRO system, combines real-time MRI, robotically driven transurethral sweeping action/thermal ultrasound, and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue.
CEOArun S. Menawat
CEOArun S. Menawat
Employees142
Employees142
HeadquartersMississauga, Ontario
HeadquartersMississauga, Ontario
Founded2008
Founded2008
Employees142
Employees142
PROF Key Statistics
Market cap192.35M
Market cap192.35M
Price-Earnings ratio-3.77
Price-Earnings ratio-3.77
Dividend yield—
Dividend yield—
Average volume289.40K
Average volume289.40K
High today$6.73
High today$6.73
Low today$5.19
Low today$5.19
Open price$6.51
Open price$6.51
Volume1.98M
Volume1.98M
52 Week high$8.95
52 Week high$8.95
52 Week low$3.76
52 Week low$3.76
Stock Snapshot
The current Profound Medical(PROF) stock price is $5.30, with a market capitalization of 192.35M. The stock trades at a price-to-earnings (P/E) ratio of -3.77.
As of 2026-03-08, Profound Medical(PROF) stock has fluctuated between $5.19 and $6.73. The current price stands at $5.30, placing the stock +2.1% above today's low and -21.2% off the high.
Profound Medical(PROF) shares are trading with a volume of 1.98M, against a daily average of 289.4K.
During the past year, Profound Medical(PROF) stock moved between $3.76 at its lowest and $8.95 at its peak.
During the past year, Profound Medical(PROF) stock moved between $3.76 at its lowest and $8.95 at its peak.
People also own
Based on the portfolios of people who own PROF. This list is generated using Robinhood data, and it’s not a recommendation.